Very low prevalence of validated <i>kelch13</i> mutations and absence of <i>hrp2/3</i> double gene deletions in South African malaria-eliminating districts (2022-2024).

ABSTRACT: South Africa is one of 25 countries identified by the World Health Organization as having the potential to eliminate malaria in the near future. In response to the emerging threat of antimalarial resistance, South Africa enhanced its surveillance programs to enable the mapping of resistance markers prevalence down to the facility level. A total of 4 471 samples, collected between January 2022 and August 2024 from healthcare facilities, and during active surveillance in malaria-eliminating districts in KwaZulu-Natal and Mpumalanga provinces, were assessed for drug (mutations in the kelch13, crt, mdr1, dhfr, and dhps genes) and diagnostic (hrp2/3 gene deletions) resistance markers using PCR and sequencing (Sanger and/or targeted amplicon) protocols.

SUBMITTER: Raman J 

PROVIDER: S-EPMC11998825 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature